Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177039 | 0.81 | LMNA (0.53) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL69696 | 0.79 | MEN1 (0.44) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL286134 | 0.79 | CA12 (0.43) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL975064 | 0.79 | SMN1; SMN2 (0.47) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL17593241 | 0.79 | GRN (0.56) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL2512844 | 0.78 | ALDH1A1 (0.47) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL286598 | 0.78 | CA12 (0.42) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL22290279 | 0.78 | CA12 (0.45) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL1196274 | 0.78 | CA12 (0.42) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL1915343 | 0.78 | CA12 (0.42) | CA12CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016040449-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD11B2 | CA12 2679/4885CA1 1125/4885CA2 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.